Press-release for stocks for gilead sciences, inc. for glpgf

entities : Gilead sciences, inc. symbols : Glpgf

save search

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
Published: 2024-01-02 (Crawled : 06:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -17.36% | O: -0.12% H: 3.52% C: 2.88%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -28.49% | O: -0.12% H: 2.22% C: 1.82%
jyseleca transfer business agreement

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -17.58% | O: 0.95% H: 0.72% C: -0.5%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -15.81% | O: 6.34% H: 2.04% C: 0.93%
presentation car-t results

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
Published: 2023-10-30 (Crawled : 20:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -13.91% | O: -0.23% H: 1.44% C: 1.22%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -11.53% | O: -0.27% H: 2.29% C: 2.04%
jyseleca transfer business

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
Published: 2023-06-15 (Crawled : 20:00) - globenewswire.com
JNJ | News | $149.12 0.82% 0.0% 9.3M

Health Technology

| -8.92% | O: 0.46% H: 0.31% C: -0.15%
LIVN | $54.005 3.2% 3.1% 710K

Health Technology

| 7.89% | O: 1.2% H: 1.92% C: 1.59%
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -15.25% | O: 0.32% H: 0.35% C: -0.49%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -31.54% | O: 0.35% H: 1.23% C: -0.49%
financial

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
Published: 2023-05-22 (Crawled : 20:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -14.84% | O: -0.03% H: 1.22% C: -0.03%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -34.7% | O: 0.31% H: 1.23% C: -0.45%
immunology

Galapagos announces first quarter 2023 financial results
Published: 2023-05-04 (Crawled : 20:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -14.74% | O: 0.29% H: 1.37% C: 1.27%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -28.22% | O: 2.86% H: 3.14% C: 2.95%
financial results

Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
Published: 2023-04-26 (Crawled : 00:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -21.78% | O: -1.58% H: 0.21% C: -0.59%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -24.24% | O: -0.08% H: 2.5% C: 2.11%
active program

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Published: 2023-02-27 (Crawled : 01:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -17.23% | O: -0.1% H: 0.15% C: -0.35%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -22.95% | O: -2.12% H: 2.19% C: 1.5%
extension study ulcerative colitis

Galapagos announces full year 2022 results and outlook for 2023
Published: 2023-02-23 (Crawled : 22:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -18.89% | O: -0.33% H: 0.04% C: -1.96%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -26.66% | O: -7.42% H: 5.64% C: 4.06%
year

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -21.85% | O: 0.19% H: 0.9% C: -0.35%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -33.3% | O: -8.03% H: 0.95% C: 0.75%
disease topline trial results

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Published: 2022-11-11 (Crawled : 12:20) - globenewswire.com
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| -18.95% | O: -1.44% H: 0.7% C: 0.5%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -29.88% | O: -0.55% H: 1.8% C: 1.41%
jyseleca chmp review

Jyseleca® approved in Japan for ulcerative colitis
Published: 2022-03-28 (Crawled : 08:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M

Health Technology

| 13.65% | O: 0.07% H: 0.7% C: 0.39%
GLPG | News | $29.09 0.03% -0.14% 80K

Health Technology

| -53.24% | O: 1.83% H: 1.42% C: -1.11%
jyseleca ulcerative colitis

Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-01 (Crawled : 22:00) - biospace.com/
RCUS 4 | $14.68 0.62% 0.0% 450K

Health Technology